ASND Stock Risk & Deep Value Analysis

Ascendis Pharma A/S

DVR Score

9.0

out of 10

Hidden Gem

What You Need to Know About ASND Stock

We analyzed Ascendis Pharma A/S using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran ASND through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.

Updated Apr 11, 2026•Run Fresh Analysis →

ASND Risk Analysis & Red Flags

What Could Go Wrong

The company's high R&D costs and current loss-making status mean it is highly dependent on the rapid commercial success of YUVIWEL and future pipeline approvals like TransCon PTH. If YUVIWEL's market adoption is slower than expected or if upcoming clinical trials for other assets fail, the company could face significant cash burn issues, requiring further dilutive capital raises that could heavily penalize the stock.

Risk Matrix

Overall

Aggressive

Financial

High

Market

Low

Competitive

High

Execution

Medium

Regulatory

Medium

Red Flags

⚠
No recent profitability metrics available, suggesting continued cash burn despite product launches.
⚠
Ongoing competitive litigation with BioMarin (potential financial and operational drain).
⚠
Dilution from recent warrant exercises, increasing share count.

Upcoming Risk Events

📅
Outcome of Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc. lawsuit
📅
Slower-than-expected commercial adoption or sales of YUVIWEL
📅
Potential clinical trial failures for other pipeline assets

When to Reconsider

🚪
Materially negative data from ongoing clinical trials for key pipeline assets (e.g., TransCon PTH, oncology).
🚪
Significant deceleration in YUVIWEL sales growth post-launch or failure to meet initial commercial targets.
🚪
Unfavorable resolution to the BioMarin lawsuit leading to substantial penalties or loss of intellectual property.

Unlock ASND Risk Analysis & Red Flags

Create a free account to see the full analysis

Investment Thesis

Ascendis Pharma is poised for significant growth, leveraging its validated TransCon platform for a diversified portfolio of rare disease and oncology assets. The recent commercialization of YUVIWEL for achondroplasia, backed by orphan drug exclusivity and compelling Phase 2 clinical data for a combination therapy, provides a substantial new revenue stream and de-risks a major pipeline asset. Coupled with the continued success of SKYTROPHA and the potential of TransCon PTH and the oncology pipeline, Ascendis demonstrates strong potential for future market leadership and a 10x return.

Is ASND Stock Undervalued?

Ascendis Pharma A/S continues to demonstrate exceptional 10x growth potential, with recent material developments significantly de-risking its pipeline and strengthening its market position. The FDA's grant of Orphan Drug Exclusivity to YUVIWEL (TransCon CNP) through 2033 and its commercial availability in the US validate the TransCon platform and provide a robust new revenue stream in the achondroplasia market. This is further bolstered by positive Phase 2 COACH trial data for the TransCon CNP + TransCon hGH combo, indicating superior growth outcomes. While the company still operates at a loss and has high R&D costs, and faces ongoing litigation with BioMarin, the strategic execution, proprietary technology, and significant market opportunities for its differentiated rare disease treatments justify a high conviction in its future market leadership and substantial growth. Cash raised from recent warrant exercises also supports its runway. Score Change Explanation: The previous analysis (2026-04-03) gave a score of 8.7/10, noting 'previously assumed successful US approval and initial commercialization of TransCon PTH.' Since then, Ascendis Pharma has announced the FDA grant of Orphan Drug Exclusivity to YUVIWEL (TransCon CNP) through Feb 27, 2033, and its commercial availability in the US. This definitively de-risks a major achondroplasia pipeline asset and transforms it into a commercial product with a significant regulatory moat. Additionally, the positive Phase 2 COACH trial Week 52 data for the TransCon CNP + TransCon hGH combo further strengthens the long-term potential of the achondroplasia franchise, showing superior growth velocity and safety. These material developments significantly bolster the company's market opportunity, competitive advantage, and future growth drivers, justifying an increase in the score. While minor dilution from warrant exercises occurred, the substantial de-risking and commercialization of a key asset far outweigh this, warranting a higher conviction in the 10x growth potential.

Unlock the full AI analysis for ASND

Get the complete DVR score, risk analysis, and more

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

ASND Price Targets & Strategy

12-Month Target

$400.00

Bull Case

$550.00

Bear Case

$180.00

Valuation Basis

Based on a 1.7x increase in market cap from current to ~$25B within 12 months, driven by successful commercialization of YUVIWEL and continued pipeline advancement.

Entry Strategy

Consider dollar-cost averaging in the range of $220-$250, looking for consolidation or pullbacks from current levels.

Exit Strategy

Take initial profits at $400, re-evaluate at $550. Set a stop loss below $200 (a key psychological support level and below the current price).

Portfolio Allocation

8% for aggressive risk tolerance

Price Targets & Strategy

Upgrade to Premium for price targets and entry/exit strategies

Is ASND Financially Healthy?

Profitability

Gross Margin

84.88%

Operating Margin

-51.66%

Net Margin

-55.25%

EPS

$-5.36

Balance Sheet

Current Ratio

1.02

Quick Ratio

0.66

Cash Flow

EBITDA

-$291.96M

Does ASND Have a Competitive Moat?

Moat Rating

🛡️ Narrow

Moat Trend

Expanding

Moat Sources

2 Identified

Intangible Assets/IP (TransCon platform, patents)Regulatory Moat (Orphan Drug Exclusivity for YUVIWEL)

The proprietary TransCon platform provides a durable competitive edge by enabling the creation of novel drug candidates with improved efficacy and patient convenience profiles. Orphan drug exclusivity for YUVIWEL protects its market position in achondroplasia for several years.

Moat Erosion Risks

•Potential for competitors to develop superior or biosimilar therapies that bypass TransCon IP.
•Patent expiry or successful patent challenges (e.g., from the BioMarin lawsuit).
•Clinical trial failures leading to a lack of pipeline replenishment.

ASND Competitive Moat Analysis

ASND Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Neutral

Institutional Sentiment

Neutral (no recent analyst upgrades/downgrades or specific institutional ownership data provided).

Insider Activity (Form 4)

Director Cha Albert reported initial beneficial ownership of 3,730 shares and multiple warrants. No Form 4 filings reported for insider buys/sells in the last 90 days. Employee warrants (22,480 shares) were granted on March 10, 2026.

Options Flow

Normal options activity (no specific data to indicate unusual put/call ratio or large block trades).

Earnings Intelligence

Next Earnings

No expected date available

Surprise Probability

Medium

Historical Earnings Pattern

No historical pattern available due to limited public data.

Key Metrics to Watch

Sales trajectory and revenue generated from YUVIWEL (TransCon CNP) post-commercializationProgress and timelines for TransCon PTH (hypoparathyroidism) regulatory filings and potential approvalsR&D expenses and cash runway outlook

Competitive Position

Top Competitor

BMY

Market Share Trend

Gaining (due to successful commercialization of SKYTROPHA and recent launch of YUVIWEL).

Valuation vs Peers

Cannot assess due to lack of ASND specific valuation data (P/E, EV/EBITDA, etc.) in the provided information.

Competitive Advantages

•Proprietary TransCon platform technology allowing for sustained-release drugs
•Orphan Drug Exclusivity for YUVIWEL provides a significant regulatory moat
•Strong clinical data validating pipeline assets

Market Intelligence

Get sentiment, earnings intel, and peer analysis with Premium

What Could Drive ASND Stock Higher?

Near-Term (0-6 months)

•YUVIWEL (TransCon CNP) US commercialization ramp-up (ongoing)
•Next earnings report (expected Q2 2026, date unconfirmed)
•Further clinical updates from the TransCon CNP + TransCon hGH combo trial
•Transition to direct ordinary share listing on Nasdaq (effective April 20, 2026)

Medium-Term (6-18 months)

•Potential regulatory milestones and commercialization of TransCon PTH (hypoparathyroidism)
•Updates on oncology pipeline assets (e.g., TransCon TNF)
•Expansion of YUVIWEL into international markets

Long-Term (18+ months)

•Establishment of market leadership in multiple rare endocrine disease segments
•Multiple blockbuster drug approvals from the TransCon platform across therapeutic areas
•Significant expansion into the oncology market with novel therapies

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for ASND?

✓
Acceleration in YUVIWEL sales growth and market adoption rates.
✓
Positive updates on the regulatory pathway and commercial launch of TransCon PTH.
✓
Consistent positive clinical data and advancement of oncology pipeline assets.

Bull Case Analysis

See what could go right with Premium

Competing with ASND

See how Ascendis Pharma A/S compares to related companies

Company	Market Cap	DVR Score	P/E	Revenue	Profit Margin	Rev Growth
Ascendis Pharma A/S ASND	—	9.0	—	$576.3M	-55.3%	0.0%

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

How Ascendis Pharma A/S Makes Money

Ascendis Pharma A/S is a global biopharmaceutical company that develops innovative therapeutics using its proprietary TransCon (Transient Conjugation) technology platform. This platform allows for the creation of prodrugs that offer controlled and sustained release of parent drugs, often enabling less frequent dosing for patients with chronic conditions. The company primarily focuses on rare diseases and oncology, generating revenue through the sales of its approved products like SKYTROPHA (for pediatric growth hormone deficiency) and now YUVIWEL (for achondroplasia), as well as through potential future product approvals and licensing agreements.

Read Full Business Model Breakdown

FAQ

What is the DVR Score for Ascendis Pharma A/S (ASND)?

As of April 11, 2026, Ascendis Pharma A/S has a DVR Score of 9.0 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the risk level for ASND stock?

Our analysis rates Ascendis Pharma A/S's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

Is Ascendis Pharma A/S's revenue growing?

Ascendis Pharma A/S has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.

Is ASND stock profitable?

Ascendis Pharma A/S has a profit margin of -55.3%. The company is currently unprofitable.

How often is the ASND DVR analysis updated?

Our AI-powered analysis of Ascendis Pharma A/S is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 11, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ASND (Ascendis Pharma A/S) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.